Result of Annual General Meeting (3983D)
May 15 2012 - 10:25AM
UK Regulatory
TIDMPRX
RNS Number : 3983D
Proximagen Group PLC
15 May 2012
15 May 2012
PROXIMAGEN GROUP PLC
("Proximagen" or "the Company")
Result of Annual General Meeting
London, UK, 15 May 2012 - Proximagen Group plc (AIM: PRX), the
rapidly growing company with a focus on the treatment of disorders
of the central nervous system and inflammatory diseases, announces
that at its Annual General Meeting which was held earlier today,
all resolutions put to shareholders were duly passed.
Enquiries
Proximagen Group plc Tel: +44 (0)20 7400 7700
James Hunter, Finance Director
Singer Capital Markets (Nominated Tel: +44 (0)20 3205 7500
Adviser)
Shaun Dobson/Claes Spang
M:Communications (Media enquiries) Tel: +44 (0)20 7920 2330
Mary-Jane Elliott / Sarah Macleod proximagen@mcomgroup.com
/ Hollie Vile
About Proximagen
Proximagen Group plc (AIM:PRX) is a European biotechnology
company focused on the development and commercialisation of novel
therapeutics for diseases of the central nervous system (CNS) and
inflammation.
The Company is developing potential new best-in-class
therapeutics in its core disease areas including epilepsy,
Parkinson's disease, and Alzheimer's disease, as well as in other
areas such as inflammation, oncology and neuropathic pain.
Proximagen has a number of existing partnerships with
pharmaceutical companies including GlaxoSmithKline, Upsher-Smith
and Lundbeck, and is developing a broad pipeline of drug candidate
programmes, with four programmes in clinical development and more
than ten earlier stage assets being progressed.
Proximagen's strategy is to advance its pipeline with its
partners and to acquire innovative drug candidates that complement
its pipeline, with the objective of scaling up its risk-mitigated
operating model and generating sustainable profits.
For more information, please visit www.proximagen.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMBKPDDQBKDFPD
Proximagen Neuroscience (LSE:PRX)
Historical Stock Chart
From May 2024 to May 2024
Proximagen Neuroscience (LSE:PRX)
Historical Stock Chart
From May 2023 to May 2024